Hope Ignited: ORIC-944 Unleashes "Best-in-Class" Potential Against Advanced Prostate Cancer!

Breakthrough Data: ORIC Pharmaceuticals today, May 28, 2025, unveiled electrifying preliminary efficacy and safety data for ORIC-944, heralding it as a "potentially best-in-class" PRC2 inhibitor for metastatic castration-resistant prostate cancer (mCRPC).
Powerful Response: In heavily pre-treated patients, ORIC-944 combined with AR inhibitors showed a stunning 59% PSA50 response rate, with a confirmed rate of 47%, and 24% achieving a profound PSA90 response, all confirmed.
Remarkable Safety & Future Path: The combination boasts a highly manageable safety profile, predominantly mild GI issues, paving the way for long-term dosing and a swift progression towards a global Phase 3 trial (NCT05413421) slated for early 2026, supercharged by a $125 million financing.

In a major stride against one of the most formidable cancers, ORIC Pharmaceuticals has pulled back the curtain on ORIC-944, and the early results are nothing short of spectacular. For patients battling metastatic castration-resistant prostate cancer (mCRPC) – a relentless disease that has often exhausted other treatment avenues – these findings, announced from South San Francisco and San Diego, represent a powerful new surge of hope.

The ongoing Phase 1b trial, testing ORIC-944 in combination with standard AR inhibitors apalutamide (ERLEADA®) and darolutamide (NUBEQA®), has demonstrated "substantial clinical activity," according to Chief Medical Officer Pratik S. Multani, M.D. The numbers speak volumes: among 17 patients who had undergone a median of three prior therapies, an impressive 59% saw their PSA levels (a key disease marker) plummet by at least half (PSA50 response). Even more profoundly, 24% achieved a PSA90 response, indicating a near-total suppression of this marker – all subsequently confirmed.

What makes ORIC-944, a potent and selective allosteric inhibitor of PRC2 via the EED subunit^{3, 6}, truly stand out is its unique mechanism, potentially reprogramming prostate cancer cells to become vulnerable to AR inhibitors again^{4, 6}. This, combined with a safety profile characterized almost entirely by mild to moderate, manageable GI-related side effects, positions it as "highly suitable for potential long term dosing."

Jacob M. Chacko, M.D., President and CEO, emphasized, "The data generated to date continue to demonstrate the potential of ORIC-944 to be a best-in-class PRC2 inhibitor that may benefit a broad range of patients with prostate cancer." Indeed, these results "compare favorably to other PRC2 inhibitor data presented earlier this year."

With further dose exploration ongoing and optimization planned for late 2025, ORIC is confidently marching towards initiating its first global registrational trial in the first half of 2026. This bold vision is backed by a concurrent $125 million private placement, extending the company's cash runway through the anticipated primary endpoint readout of this pivotal trial. For patients and the oncology community, ORIC-944 is not just a drug candidate; it's a beacon, potentially rewriting the future of advanced prostate cancer treatment.

Hope Ignited: ORIC-944 Unleashes "Best-in-Class" Potential Against Advanced Prostate Cancer!

References

Stay Updated!